{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:32Z","timestamp":1793664812056,"version":"4.5.1"},"reference-count":169,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.kint.2026.02.029","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:44:39Z","timestamp":1774583079000},"page":"548-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference"],"prefix":"10.1016","volume":"110","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7988-3082","authenticated-orcid":false,"given":"Isabelle","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke R.","family":"Brix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-8651","authenticated-orcid":false,"given":"Kirk N.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-2862","authenticated-orcid":false,"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1941","authenticated-orcid":false,"given":"Sydney C.W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6385-9862","authenticated-orcid":false,"given":"Nicola M.","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-1959","authenticated-orcid":false,"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-2831","authenticated-orcid":false,"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-7812","authenticated-orcid":false,"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Alberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Barnas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak Mao","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Yu-Hin Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Duivenvoorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Eggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Georges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre G.","family":"Gontijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittan","family":"Kopittke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Leandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Mej\u00eda-Vilet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L.","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber S.","family":"Podoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Rojas-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira Z.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Suan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita S.","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh Geot","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Kim","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.02.029_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.02.029_bib2","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1001\/jama.2025.19316","article-title":"Rituximab for relapsing nephrotic syndrome in adults: a randomized clinical trial","volume":"334","author":"Isaka","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.02.029_bib3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.kint.2026.02.029_bib53","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1182\/blood.2024025413","article-title":"CAR T cells in autoimmunity: game changer or stepping stone?","volume":"145","author":"Mougiakakos","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.02.029_bib8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.02.029_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.kint.2026.02.029_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jimmun\/vkaf008","article-title":"Can autoimmune disease be cured by deep CD19+ cell depletion?","volume":"214","author":"Suan","year":"2025","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib11","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.02.029_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997","volume":"30","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0272-6386(00)70258-7","article-title":"Changing incidence of glomerular diseases in adults","volume":"35","author":"Braden","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib17","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","article-title":"Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome","volume":"10","author":"Colucci","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib19","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.029_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","article-title":"Pathogenicity of human anti-PLA 2 R1 antibodies in minipigs: a pilot study","volume":"34","author":"Reinhard","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.02.029_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2022.09.008","article-title":"Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice","volume":"103","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.kint.2023.07.024","article-title":"Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy","volume":"104","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.kint.2025.08.026","article-title":"Patient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice","volume":"108","author":"Zahner","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib26","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib28","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2215\/CJN.03850414","article-title":"M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy","volume":"9","author":"Hoxha","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ekir.2017.10.013","article-title":"The role of PLA2R antibody in treatment of membranous nephropathy","volume":"3","author":"Dahan","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/ckj\/sfx128","article-title":"The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation","volume":"11","author":"Xipell","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.02.029_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221293","article-title":"Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy","volume":"14","author":"Mahmud","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2026.02.029_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.akdh.2024.10.004","article-title":"Podocytopathies","volume":"32","author":"Navarro-Torres","year":"2025","journal-title":"Adv Kidney Dis Health"},{"key":"10.1016\/j.kint.2026.02.029_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib35","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.kint.2023.11.022","article-title":"A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence","volume":"105","author":"Shirai","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.kint.2025.01.019","article-title":"Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy","volume":"107","author":"Hengel","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.kint.2024.07.022","article-title":"Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft","volume":"106","author":"Batal","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.kint.2025.02.028","article-title":"Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis","volume":"108","author":"Shu","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","article-title":"Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants","volume":"106","author":"Raglianti","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186769","article-title":"Passive transfer of patient-derived anti-nephrin autoantibodies causes a podocytopathy with minimal change lesions","volume":"135","author":"Hengel","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.02.029_bib42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.0000000642","article-title":"Anti-slit antibodies against podocin and Kirrel1 in pediatric and adult podocytopathies","volume":"36","author":"Raglianti","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726428","article-title":"CyTOF-enabled analysis identifies class-switched B cells as the main lymphocyte subset associated with disease relapse in children with idiopathic nephrotic syndrome","volume":"12","author":"Fribourg","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","article-title":"Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome","volume":"84","author":"Bhatia","year":"2018","journal-title":"Pediatr Res"},{"key":"10.1016\/j.kint.2026.02.029_bib45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.kint.2023.06.013","article-title":"Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing\/steroid-dependent nephrotic syndrome","volume":"104","author":"Colucci","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-025-00653-y","article-title":"Lupus nephritis","volume":"11","author":"Parodis","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.02.029_bib48","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib50","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.3390\/jcm12216927","article-title":"A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2026.02.029_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B cells and plasma cells in glomerular diseases: translational perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.kint.2026.02.029_bib54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib57","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20243d4074tq","article-title":"Safety, tolerability, and efficacy of mezagitamab (TAK-079) as add-on to standard of care therapy in individuals with primary IgA nephropathy: interim results from an open-label phase 1b study: FR-PO857","volume":"35","author":"Barratt","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib61","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib62","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib65","article-title":"Results from longer follow-up with povetacicept, an enhanced dual BAFF\/APRIL antagonist, in IgA nephropathy (RUBY-3 study): FR-PO854","volume":"35","author":"Madan","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1016\/j.kint.2026.02.029_bib66","article-title":"#2859 ORIGIN 2b: changes in Gd-IgA1 and eGFR after discontinuation of atacicept treatment in IgA nephropathy","volume":"40","author":"Barratt","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib67","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib68","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib70","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib72","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib73","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib74","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/ndt\/gfab037","article-title":"Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens","volume":"36","author":"Ramachandran","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"10.1016\/j.kint.2026.02.029_bib75","first-page":"S1","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib76","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100853","article-title":"Obinutuzumab in refractory membranous nephropathy: a case series","volume":"6","author":"Lin","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2026.02.029_bib78","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib79","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib80","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib81","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20249xdwh001","article-title":"Belimumab and rituximab for the treatment of primary membranous nephropathy: initial REBOOT results: TH-PO586","volume":"35","author":"Nachman","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib169","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ekir.2025.10.029","article-title":"Povetacicept for IgA nephropathy and primary membranous nephropathy","volume":"11","author":"Madan","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.02.029_bib83","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000501858","article-title":"Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: preliminary findings with double filtration plasmapheresis and ofatumumab","volume":"144","author":"Podesta","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2026.02.029_bib84","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib85","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"Muller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.02.029_bib86","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.02.029_bib87","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.02.029_bib88","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.kint.2025.09.028","article-title":"Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells","volume":"109","author":"Altun","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib90","first-page":"CD002290","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","volume":"11","author":"Larkins","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2026.02.029_bib91","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","article-title":"Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome","volume":"9","author":"Liu","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib92","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2499902","article-title":"The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial","volume":"47","author":"Sheng","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.02.029_bib93","first-page":"588","article-title":"Efficacy and safety of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"21","author":"Luo","year":"2025","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.kint.2026.02.029_bib94","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2215\/CJN.08570722","article-title":"Use of rituximab in childhood idiopathic nephrotic syndrome","volume":"18","author":"Chan","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib95","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2021050643","article-title":"Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome","volume":"33","author":"Iijima","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib96","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","article-title":"Update on the treatment of steroid-sensitive nephrotic syndrome","volume":"37","author":"Zotta","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib97","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jaci.2018.02.017","article-title":"Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood","volume":"141","author":"Blanco","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib98","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1681\/ASN.2021040561","article-title":"Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib99","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12882-025-04035-0","article-title":"Long-term efficacy of rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome","volume":"26","author":"Feder","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000535010","article-title":"Efficacy of rituximab for minimal change disease and focal segmental glomerulosclerosis with frequently relapsing or steroid-dependent nephrotic syndrome in adults: a Chinese multicenter retrospective study","volume":"55","author":"Lan","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib102","first-page":"577","article-title":"Rituximab therapy in adults with steroid-dependent nephrotic syndrome","volume":"19","author":"Zhong","year":"2023","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.kint.2026.02.029_bib103","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000300","article-title":"Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment","volume":"93","author":"Iwabuchi","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.kint.2026.02.029_bib104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5414\/CN107092","article-title":"Rituximab in adult patients with immunosuppressive-dependent minimal change disease","volume":"76","author":"Hoxha","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib105","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","article-title":"Rituximab as initial therapy in adult patients with minimal change disease","volume":"8","author":"Guan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib106","article-title":"The efficacy and safety of half-dose glucocorticoids combined with rituximab versus high-dose glucocorticoids for initial treatment of minimal change disease: a single-center experience","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2026.02.029_bib107","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00467-021-05175-9","article-title":"Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study","volume":"37","author":"Vivarelli","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib108","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ekir.2024.04.006","article-title":"Combined rituximab and daratumumab treatment in difficult-to-treat nephrotic syndrome cases","volume":"9","author":"Angeletti","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib109","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib110","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14544","article-title":"Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab","volume":"27","author":"Delbet","year":"2023","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib111","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ajt.2024.02.016","article-title":"Reply to Angeletti et al\u2014efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Dossier","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib112","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.02.029_bib113","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib114","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib115","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001436","article-title":"Obinutuzumab effectively depletes key B-cell subsets in blood and tissue in end-stage renal disease patients","volume":"9","author":"Looney","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2026.02.029_bib116","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2025ap9ae1n1","article-title":"Beyond clinical response in the REGENCY trial: the impact of obinutuzumab on histologic remission in patients with active lupus nephritis: SA-OR084","volume":"36","author":"Rovin","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib117","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"issue":"1S","key":"10.1016\/j.kint.2026.02.029_bib118","first-page":"S1","article-title":"KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib119","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.02.029_bib120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib121","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2026.02.029_bib122","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib123","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.02.029_bib124","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib153","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib154","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib126","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2026.02.029_bib127","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.02.029_bib128","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.ekir.2025.05.016","article-title":"Point-of-care anti-CD19-CAR T-cell therapy induces renal remission in refractory myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"10","author":"Schultze-Florey","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.02.029_bib129","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib130","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib131","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib132","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1681\/ASN.2020081208","article-title":"O- and N-Glycosylation of serum immunoglobulin A is associated with IgA nephropathy and glomerular function","volume":"32","author":"Dotz","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib133","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2215\/CJN.01150113","article-title":"Renal interstitial infiltration and tertiary lymphoid organ neogenesis in IgA nephropathy","volume":"9","author":"Pei","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib134","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfae173","article-title":"IgA class-switched CD27\u2212CD21+ B cells in IgA nephropathy","volume":"40","author":"Popova","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib135","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106838","article-title":"Alterations of B-cell subsets in peripheral blood from adult patients with idiopathic membranous nephropathy","volume":"266","author":"Wang","year":"2024","journal-title":"Immunol Lett"},{"key":"10.1016\/j.kint.2026.02.029_bib137","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00467-018-4095-z","article-title":"B cell phenotype in pediatric idiopathic nephrotic syndrome","volume":"34","author":"Colucci","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib138","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fped.2019.00377","article-title":"Altered B-lymphocyte homeostasis in idiopathic nephrotic syndrome","volume":"7","author":"Ling","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.kint.2026.02.029_bib139","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","article-title":"The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome","volume":"24","author":"Shao","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379924","article-title":"A novel flow cytometry panel to identify prognostic markers for steroid-sensitive forms of idiopathic nephrotic syndrome in childhood","volume":"15","author":"Riganati","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib141","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.3390\/ijms24097687","article-title":"Immunophenotypic alterations in adult patients with steroid-dependent and frequently relapsing nephrotic syndrome","volume":"24","author":"Casiraghi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.02.029_bib142","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/ndt\/gfaa279","article-title":"Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults","volume":"36","author":"Oniszczuk","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib143","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1038\/s41467-023-43504-8","article-title":"The extrafollicular B cell response is a hallmark of childhood idiopathic nephrotic syndrome","volume":"14","author":"Al-Aubodah","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.02.029_bib144","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf100","article-title":"Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases","volume":"18","author":"Hengel","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2026.02.029_bib145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000545706","article-title":"Quo vadis standardization of anti-nephrin antibody detection?","volume":"5","author":"Mirioglu","year":"2025","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib146","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.kint.2025.05.018","article-title":"Evaluation of methodologies in anti-nephrin autoantibody detection","volume":"108","author":"Liu","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib147","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.kint.2025.04.015","article-title":"Anti-nephrin antibodies guide living donor kidney transplantation in a pediatric patient with primary focal segmental glomerular sclerosis","volume":"108","author":"Habbig","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib148","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'Era","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.kint.2026.02.029_bib149","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.02.029_bib150","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.02.029_bib151","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.06460622","article-title":"Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement","volume":"18","author":"Casal Moura","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib152","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2026.02.029_bib155","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-024-07748-8","article-title":"Immunological memory diversity in the human upper airway","volume":"632","author":"Ramirez","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.kint.2026.02.029_bib156","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib157","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fimmu.2015.00228","article-title":"Mechanisms of autoantibody production in systemic lupus erythematosus","volume":"6","author":"Han","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib158","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/eji.201041354","article-title":"Plasma cells in systemic lupus erythematosus: the long and short of it all","volume":"41","author":"Liu","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.kint.2026.02.029_bib159","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.02.029_bib160","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","volume":"97","author":"Chan","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.02.029_bib161","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","article-title":"Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey","volume":"38","author":"Zurowska","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib162","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2026.02.029_bib163","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2017.12.061","article-title":"Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents","volume":"196","author":"Kamei","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.kint.2026.02.029_bib164","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study","volume":"33","author":"Chan","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.02.029_bib165","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.kint.2026.02.029_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.kint.2026.02.029_bib167","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2026.02.029_bib168","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.3390\/curroncol30050378","article-title":"Management and prevention of cellular-therapy-related toxicity: early and late complications","volume":"30","author":"Mucha","year":"2023","journal-title":"Curr Oncol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:44:37Z","timestamp":1787219077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826002267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":169,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0085253826002267"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.029","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}